Literature DB >> 34324927

Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program.

Benjamin A Steinberg1, Mingyuan Zhang2, Jason Bensch2, Ann Lyons2, T Jared Bunch2, Jonathan P Piccini3, Alfonso Siu2, John A Spertus4, Josef Stehlik2, Peter Wohlfahrt2, Tom Greene2, Rachel Hess2, James C Fang2.   

Abstract

BACKGROUND: Atrial fibrillation (AF) frequently complicates heart failure (HF), and each is associated with lower overall health-related quality of life. We aimed to quantify the incremental burden of AF on the health-related quality of life of patients with HF in clinical practice. METHODS AND
RESULTS: We used data from the Utah mEVAL program to analyze patient-reported outcomes (PROs) among patients with HF with and without AF. The primary outcome was the HF-specific Kansas City Cardiomyopathy Questionnaire, with generic PROs as secondary outcomes. Among 1707 patients with HF, 36% had AF (n = 616). Those with HF and AF were older (mean age 69 years vs 58 years, P < .001), more likely to have prior stroke (29% vs 17%, P < .001) and ischemic cardiomyopathy (28% vs 23%, P = .01), but had similar ejection fractions (mean 44% each, P = .6). After adjustment, and compared with HF alone, HF with AF was associated with worse Kansas City Cardiomyopathy Questionnaire scores (adjusted mean difference -3.45, 95% confidence interval [CI] -6.24 to -0.65), and worse Patient-Reported Outcomes Measurement Information System physical function scores (adjusted mean difference -1.63, 95% CI -2.59 to -0.67). The difference in visual analog scale general health was borderline (adjusted mean difference -2.01, 95% CI -4.51 to 0.49), and Patient-Reported Outcomes Measurement Information System depression scores were similar (adjusted mean difference 0.54, 95% CI -0.48 to 1.57).
CONCLUSIONS: AF complicates nearly one-third of HF cases, and patients with HF and AF are substantially older and sicker. After adjustment, AF was independently associated with worse disease-specific and overall health-related quality of life than HF alone. Whether maintaining sinus rhythm can improve the HF-related health status of patients with HF in clinical practice should be explored further.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; health-related quality of life; heart failure; patient-reported outcomes

Mesh:

Substances:

Year:  2021        PMID: 34324927      PMCID: PMC8748275          DOI: 10.1016/j.cardfail.2021.07.009

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  27 in total

Review 1.  Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation.

Authors:  Kevin M Trulock; Sanjiv M Narayan; Jonathan P Piccini
Journal:  J Am Coll Cardiol       Date:  2014-08-19       Impact factor: 24.094

Review 2.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy.

Authors:  William H Maisel; Lynne Warner Stevenson
Journal:  Am J Cardiol       Date:  2003-03-20       Impact factor: 2.778

3.  Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients.

Authors:  Kathleen J Yost; David T Eton; Sofia F Garcia; David Cella
Journal:  J Clin Epidemiol       Date:  2011-05       Impact factor: 6.437

4.  Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure: A Meta-analysis of Randomized Controlled Trials.

Authors:  Mohit K Turagam; Jalaj Garg; William Whang; Samantha Sartori; Jacob S Koruth; Marc A Miller; Noelle Langan; Aamir Sofi; Anthony Gomes; Subbarao Choudry; Srinivas R Dukkipati; Vivek Y Reddy
Journal:  Ann Intern Med       Date:  2018-12-25       Impact factor: 25.391

5.  Atrial fibrillation ablation in practice: assessing CABANA generalizability.

Authors:  Peter A Noseworthy; Bernard J Gersh; David M Kent; Jonathan P Piccini; Douglas L Packer; Nilay D Shah; Xiaoxi Yao
Journal:  Eur Heart J       Date:  2019-04-21       Impact factor: 29.983

6.  Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.

Authors:  Daniel B Mark; Kevin J Anstrom; Shubin Sheng; Jonathan P Piccini; Khaula N Baloch; Kristi H Monahan; Melanie R Daniels; Tristram D Bahnson; Jeanne E Poole; Yves Rosenberg; Kerry L Lee; Douglas L Packer
Journal:  JAMA       Date:  2019-04-02       Impact factor: 56.272

7.  Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.

Authors:  Susan M Joseph; Eric Novak; Suzanne V Arnold; Philip G Jones; Himad Khattak; Anne E Platts; Victor G Dávila-Román; Douglas L Mann; John A Spertus
Journal:  Circ Heart Fail       Date:  2013-10-15       Impact factor: 8.790

8.  Patient reported outcomes - experiences with implementation in a University Health Care setting.

Authors:  Joshua Biber; Dominik Ose; Jenny Reese; Anna Gardiner; Julio Facelli; Joshua Spuhl; Darrel Brodke; Vivian S Lee; Rachel Hess; Howard Weeks
Journal:  J Patient Rep Outcomes       Date:  2018-08-17

9.  Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire.

Authors:  John A Spertus; Philip G Jones
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-09

Review 10.  Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop.

Authors:  Sana M Al-Khatib; Emelia J Benjamin; Christine M Albert; Alvaro Alonso; Cynthia Chauhan; Peng-Sheng Chen; Anne B Curtis; Patrice Desvigne-Nickens; Jennifer E Ho; Carolyn S P Lam; Mark S Link; Kristen K Patton; Margaret M Redfield; Michiel Rienstra; Yves Rosenberg; Renate Schnabel; John A Spertus; Lynne Warner Stevenson; Mellanie True Hills; Adriaan A Voors; Lawton S Cooper; Alan S Go
Journal:  Circulation       Date:  2020-06-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.